BOT

0.00%

38.0¢ botanix pharmaceuticals ltd

Thought you were moving on Southoz because you had a higher call...

First 59 Last

Share
Profile

Follow
kawartha

712 Posts.

84

24/10/19

23:31

Post #: 41058749
Share

Originally posted by Southoz: ↑

Mmm … its complicated; because it can be both. A trial pharmacist can “manufacture” an investigational product by compounding; mixing up a brew.

But more commonplace and in a trial like the one here - yes “manufacture” would encompass the dolling of individual portions and the labelling. The site takes over with respect to stock management, storage, preparation and dispensing.

But look take a step back here.

There is always 1% of truth to these company dog ate my homework type explanations to failed trial results. So sure there might have been minor variation in vehicle quality but nothing to the extent that explains that placebo response.

But lets say it was true. What would happen. Well basically it’s a runway train scenario.

The PIs have no choice but to notify their IRB of this protocol violation (which this is) that has essentially negated the scientific value of the US component of this trial. Many US participants have essentially wasted their time taking part in this trial.

The IRB has no choice but to inform the FDA. The FDA would inspect those manufacturing sites. Given the difficulty BOT seem to be having in getting on top of what has happened the record keeping quality control must be terrible. The FDA would close them down.

Why this big drama – because of the safety risk.

A child experiences an unusual adverse health event. The mother takes him to ED. She informs the clinician the child is on a clinical trial for a new acne treatment. She doesn’t know what it is exactly or whether the child is in the placebo or active arm.

The treating clinician will ring the trial pharmacist / Study Coordinator who will break the blind to inform the clinician what treatment the child is receiving. Good news the Study Coordinator says … it’s the placebo. A vehicle … completely harmless. Thanks says the treating doctor we can rule that out. But it turns out the placebo was really an active. What a potential disaster.

This just can’t be allowed to happen.

So have the PIs / BOT informed the US IRBs of this stuff-up? Has the FDA been notified? If not - why not? If this manufacturing stuff-up is true and the PIs and BOT haven’t notified the IRB / FDA they would be in breach of a dozen US regulatory laws.

They haven’t because the manufacturing variation (or problems) is in reality inconsequential. It is only in BOTs head that this caused the trial to fail. No-one else thinks this because if they did then they would have reported it because they don’t want to go to jail.

Expand

Thought you were moving on Southoz because you had a higher call of duty as stated yesterday.

I think I will go with Vince who has launched 20 branded dermatology products and was instrumental in the sale of Anacor for a mere US$5.2 Billion

Go buy some glue to fix your broken record

BOT Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

There are more pages in this discussion • 101 more messages in this thread...

First 59 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 38.0¢		Change 0.000(0.00%)		Mkt cap ! $689.3M

Open	High	Low	Value	Volume
38.0¢	38.5¢	37.5¢	$1.784M	4.691M

Buyers (Bids)

No.	Vol.	Price($)
1	248028	38.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.5¢	356327	6

View Market Depth

No.	Vol.	Price($)
4	257702	0.375
5	286143	0.370
5	154861	0.365
8	220465	0.360
6	256198	0.355

Price($)	Vol.	No.
0.385	169178	3
0.390	230820	4
0.395	471715	8
0.400	203081	7
0.405	230000	3

Last trade - 16.10pm 27/09/2024 (20 minute delay)

BOT (ASX) Chart

Thought you were moving on Southoz because you had a higher call...

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thought you were moving on Southoz because you had a higher call...

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News